Aug. 26 at 2:08 PM
$AVDL: Avadel Pharma is a new member of our GROWX rankings this week. Avadel has one commercial product, LUMRYZ, which was approved by the FDA on May 1, 2023. The company is profitable and growing the top line nicely with 1H25 revs up 76% yr/yr to
$120.6 mln. Its strong Q2 report led Avadel to increase FY25 revenue guidance to
$265-275 mln. Other additions to the rankings this week include
$ASM,
$MEG, and
$BLZE.
#Top100 #growthstocks #relativestrength #EmergingGrowth #TodaysFreeFeature
View other additions: https://www.briefing.com/todays-free-feature?utm_campaign=freefeature&utm_medium=social&utm_source=st&utm_content=link